ProMIS Neurosciences Inc.

Last updated September 27, 2026

Organization details

Legal name
ProMIS Neurosciences Inc.
Former names
Amorfix Life Sciences Ltd
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Canada (Federal Level)
Headquarters city
Toronto
Headquarters country
Canada
Fiscal year end
December
Ticker symbol
PMN
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001374339

Board of directors

Chief executives

Gail M. Farfel · Chief Executive Officer
Dates unknown
Neil K. Warma · Chief Executive Officer
Dates unknown

Board connections

2 of this board's directors also sit on 2 other boards. 2 are in the same sector.

Network of ProMIS Neurosciences Inc.'s board connections CAMP4 Therapeutics Corporation CAMP4 Therapeutics Cor... Tectonic Therapeutic Inc. Tectonic Therapeutic I... Gail M. Farfel Gail M. Farfel Josh Mandel-Brehm Josh Mandel-Brehm ProMIS Neurosciences Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$8,876,603
11 purchases by 5 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Nov 4, 2026 Eugene Williams Director Open-market purchase +26,500 $3.43 $90,895
Nov 2, 2026 Neil Cashman Director, Officer (Chief Scientific Officer) Open-market purchase +10,000 $3.86 $38,600
Oct 30, 2026 Eugene Williams Director Open-market purchase +1,316 $3.99 $5,251
Aug 5, 2026 Kaplan Johanne Officer (Chief Development Officer) Open-market purchase +2,280 $13.30 $30,324
Apr 22, 2026 Patrick D. Kirwin Director Open-market purchase +4,000 $11.33 $45,320
Mar 5, 2026 Eugene Williams Director Open-market purchase +2,000 $24.40 $48,800
Mar 4, 2026 Eugene Williams Director Open-market purchase +2,000 $24.00 $48,000
Mar 3, 2026 Eugene Williams Director Open-market purchase +1,000 $21.89 $21,890
Mar 2, 2026 Eugene Williams Director Open-market purchase +1,000 $22.53 $22,530
Feb 19, 2026 Kaplan Johanne Officer (Chief Development Officer) Open-market purchase +1,629 $15.35 $25,005
Feb 3, 2026 Neil Cashman Director, Officer (Chief Scientific Officer) Grant or award +4,122 $12.13 $50,000
Feb 3, 2026 Kaplan Johanne Officer (Chief Development Officer) Grant or award +2,060 $12.13 $24,988
Feb 3, 2026 Neil K. Warma Director, Officer (Chief Executive Officer) Grant or award +6,183 $12.13 $75,000
Feb 3, 2026 Milbury Max A. Principal Accounting Officer Grant or award +6,595 $12.13 $79,997
Feb 3, 2026 Patrick D. Kirwin Director Grant or award +3,050 $12.13 $36,997

Organizations in the same sector, closest in location and size first.

Questions about ProMIS Neurosciences Inc.

Who is the CEO of ProMIS Neurosciences Inc.?

Gail M. Farfel is ProMIS Neurosciences Inc.'s Chief Executive Officer.

How many directors are on ProMIS Neurosciences Inc.'s board?

ProMIS Neurosciences Inc.'s board has 10 directors: Eugene Williams, Gail M. Farfel, Gavin T. Malenfant, Josh Mandel-Brehm, Madge K. Shafmaster, Neil Cashman, Neil K. Warma, Patrick D. Kirwin, Slanix Paul Alex and William W. Wyman.

Are ProMIS Neurosciences Inc. insiders buying or selling shares?

Over the last 12 months, ProMIS Neurosciences Inc. insiders bought $8.9 million of shares in 11 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="promis-neurosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.